![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1635933
Ç÷°ü Æó¼â ±â±â ½ÃÀå º¸°í¼ : Á¦Ç°º°, ¾×¼¼½ºº°, ½Ã¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)Vascular Closure Devices Market Report by Product, Access, Procedure, End-User, and Region 2025-2033 |
Ç÷°ü Æó¼â ±â±â ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 15¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 24¾ï ´Þ·¯¿¡ µµ´ÞÇÏ¿© 2025³âºÎÅÍ 2033³â±îÁö 4.9%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°üÁúȯ(CVDs) À¯º´·ü Áõ°¡, Ç÷°ü ½Ã¼ú Áõ°¡, Æó¼âÇü ±â±â ±â¼ú ¹ßÀü, ÃÖ¼Òħ½À(MI) Ä¡·á¸¦ ¼±È£ÇÏ´Â Àα¸Åë°èÇÐÀû °í·ÉÈ, ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø, ¾÷°èÀÇ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê, ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÁöÃâ Áõ°¡, ±â±â ½ÂÀÎ ¹®Á¦, Áö¼ÓÀûÀÎ Çõ½Å ³ë·Â µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù. ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.
Ç÷°ü Æó¼â ±â±â(VCD)´Â Ç÷°üÁ¶¿µ¼ú ÈÄ µ¿¸Æ¿¡ »ý±ä ÀÛÀº ±¸¸ÛÀ» Áï½Ã ¸·±â À§ÇØ Àü ¼¼°è º´¿ø, Áø·á¼Ò, Àü¹® ¼ö¼ú ¼¾ÅÍ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ¿¡¼ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ±â±â´Â ±âÁ¸ÀÇ ±â°èÀû ¾Ð¹Ú¿¡ ºñÇØ Çã¹÷Áö °æ·Î·Î Ä«Å×ÅÍ Ä¡·á¸¦ ¹Þ´Â ȯÀÚµé »çÀÌ¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ±â±¸´Â »çŸ±¸´Ï õÀÚ ºÎÀ§¿¡¼ Áï°¢ÀûÀÎ ÃâÇ÷ÀÇ À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. VCD´Â ÁöÇ÷ ½Ã°£ ´ÜÃà, ȯÀÚ À̵¿ ¿ëÀ̼º, Àå±â ´©¿öÀִ ȯÀÚÀÇ ºÒÆí°¨ °¨¼Ò, ÀÔ¿ø ±â°£ ´ÜÃà, ´ëÅðµ¿¸Æ ÇÕº´Áõ ¿¹¹æ µî ´Ù¾çÇÑ ÀÌÁ¡À» Á¦°øÇϱ⠶§¹®¿¡ Àü ¼¼°èÀûÀ¸·Î ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÇöÀç Àü ¼¼°èÀûÀ¸·Î ³úÁ¹Áß, °ü»óµ¿¸ÆÁúȯ, ¸»Ãʵ¿¸ÆÁúȯ, ´ëµ¿¸ÆÁúȯ µî ½ÉÇ÷°üÁúȯ(CVD)ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ±Þ¼ºÀåÇÏ´Â ÇコÄÉ¾î »ê¾÷°ú ÇÔ²² ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î, CVD Áø´Ü ¹× Ä¡·á¸¦ À§ÇÑ Ä«Å×ÅÍ ¹× ÁßÀçÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¾÷°è ÅõÀÚÀڵ鿡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ø ¹× ¼ö¼ú ¼¾ÅÍ¿¡¼ ÷´Ü ¼ö¼ú Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °ü»óµ¿¸Æ Á¶¿µ¼ú ¹× ±âŸ ÁßÀçÀû ½Ã¼ú¿¡¼ Ç÷°ü Á¢±ÙÀ» À§ÇÑ ´ëÅð°ñ ¸ðµå¿¡ ´ëÇÑ ¼ö¿ä°¡ Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ºÀÇÕ ¹× ÈäÅ͸¦ ÇÇÇϱâ À§ÇÑ ºñħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÇÔ²² ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, ¼ö¼ú Áß È¯ÀÚÀÇ È¿°úÀûÀÎ ÃâÇ÷ °ü¸®¿¡ ´ëÇÑ ÀÇ»çÀÇ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ ¾÷°è¿¡¼ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä Á¦Á¶¾÷üµéÀº ´ë±¸°æ Ç÷°ü Æó¼â ±â±â Á¦Á¶¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÁÖ¿ä ½ÃÀå ÁøÀÔÀÚµéÀÌ Çõ½ÅÀûÀÎ ÀåÄ¡ÀÇ µî·Ï ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½À¼º, ³ôÀº ȯÀÚ ¿¹ÈÄ, Á¶±â º¸Çà, ½Ã¼ú Áß Æí¾ÈÇÔ µî VCDÀÇ ÀåÁ¡¿¡ ´ëÇÑ ´ëÁßÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
The global vascular closure devices market size reached USD 1.56 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.40 Billion by 2033, exhibiting a growth rate (CAGR) of 4.9% during 2025-2033. Increasing prevalence of cardiovascular disease (CVDs), rising vascular procedures, technological advancements in closure devices, aging population demographics favoring minimally invasive (MI) treatments, regulatory support, strategic industry initiatives, expanding healthcare expenditure in emerging markets, challenges in device approval, and ongoing innovation efforts are some of the factors stimulating the market expansion.
Vascular closure devices (VCDs) are used in hospitals, clinics, and specialty and ambulatory surgery centers across the globe to immediately seal the small puncture made in an artery after an angiogram. These devices are widely utilized among patients undergoing catheterization via the femoral route as compared to traditional mechanical compression. They assist in reducing the risk of immediate bleeding from the groin puncture site. Besides this, they also aid in setting a large body habitus and anticoagulation and antiplatelet therapies. As they offer various benefits, such as reducing the time to hemostasis, facilitating patient mobilization, lowering patient discomfort associated with prolonged bed rest, decreasing hospital stays, and preventing femoral artery complications, the demand for VCDs is increasing worldwide.
At present, there is a rise in the prevalence of cardiovascular diseases (CVDs), such as stroke and coronary heart, peripheral arterial, and aortic diseases, across the globe. This, along with the burgeoning healthcare industry, represents one of the key factors supporting the growth of the market. Besides this, the escalating demand for catheterization and interventional procedures for diagnosing and treating CVDs is offering lucrative growth opportunities to industry investors. In addition, the growing demand for advanced surgical equipment in hospitals and surgical centers is positively influencing the market. Moreover, there is an increase in the demand for femoral mode for vascular access during coronary angiography and other interventional procedures around the world. This, coupled with the growing demand for non-invasive procedures to avoid stitches and scarring, is positively influencing the market. Apart from this, the rising focus of doctors on effective blood loss management in patients during surgical procedures is strengthening the growth of the market. Additionally, key manufacturers operating in the industry are focusing on manufacturing large-bore vascular closure devices. In line with this, the increasing number of registrations for innovative devices by key market players is propelling the growth of the market. Furthermore, the rising awareness among the masses about the benefits of VCDs, such as enabling minimal invasions, high patient outcomes, early ambulation, and comfort during procedures, is bolstering the growth of the market.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.